Latest studies
- Active not recruitingPHASE2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study is testing a new medicine, Selinexor, for people in the UK with a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded to previous treatments. It aims to see if Selinexor can help when other options haven't worked.
Diffuse Large B-cell LymphomaBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
This study is looking at a new way to treat follicular lymphoma, a type of cancer. It compares a drug called Ibrutinib with a standard treatment, Rituximab. The aim is to see if adding Ibrutinib helps people live longer without their cancer getting worse.
Follicular LymphomaBelgium - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma
This study is looking at a new, tiny implant for people with glaucoma. It slowly releases medicine called timolol inside the eye to see how safe it is and if people can tolerate it well. This is an early-stage study to test it in humans for the first time.
GlaucomaBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)
This study is testing a new medicine called TEV-48574 for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, comparing it to a dummy medicine.
Crohn’s disease, Ulcerative colitisBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of heart failure where the heart struggles to pump blood effectively. It aims to see if different doses are safe and if the medicine helps improve heart health over 12 weeks.
Heart failure (HF) with reduced ejection fraction (HFrEF)Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
This study is looking into a new medication called Tinlarebant for young people with Stargardt disease. It aims to see if the medication is safe and can slow down the development of the condition over about two years, compared to a dummy treatment.
Stargardt DiseaseBelgium - Active not recruitingPHASE3
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
This study is looking at a medicine called fenfluramine in very young children (aged 1 to just under 2 years old) with a rare type of epilepsy called Dravet syndrome. It aims to check if the medicine is safe and well-tolerated at different doses.
Dravet SyndromeBelgium - Ongoing, recruitingPhase II and Phase III (Integrated)
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis.
This study is testing a new medicine called Belapectin. It's for people with liver scarring (cirrhosis) from NAFLD, to see if it can stop a serious problem called oesophageal varices from forming. Researchers want to know if it's safe and if it works better than a dummy medicine.
Esophageal Varices in NASH CirrhosisBelgium - Active not recruitingPHASE2, PHASE3
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
This study looks at new ways to treat medulloblastoma, a type of brain tumour, in children and young people. It aims to find the best treatments based on the tumour's specific characteristics, hoping to improve the chances of recovery with fewer side effects.
Brain TumorsBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics profile of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis.
This study is looking into a new medicine, BI 764198, for people with a kidney condition called focal segmental glomerulosclerosis. We want to see if it helps reduce protein in the urine and if it's safe to use, compared to a dummy pill.
Focal segmental glomerulosclerosisBelgium - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer
This study is testing new treatments for advanced non-small cell lung cancer. It combines a new medicine, vudalimab, or an existing one, pembrolizumab, with chemotherapy. Doctors will be looking at how safe and effective these combinations are for patients.
Advanced Non-small Cell Lung CancerBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)
This study is testing a new treatment combination for locally advanced cervical cancer. It compares standard chemotherapy and radiation with the same treatment plus a new drug, pembrolizumab (Keytruda), to see if it helps patients live longer and stops the cancer from growing.
Locally Advanced Cervical CancerBelgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without food and with or without fluconazole
This study is looking at how a new medicine, called aticaprant, works in healthy people. We want to find out how long it stays in the body, and if food or another common medicine (fluconazole) changes how it works.
Healthy Adult ParticipantsBelgium - Recruiting
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
This study looks at how well a medicine called Atezolizumab works and how happy people are with it when used for lung cancer or a type of liver cancer in normal NHS care. It also checks for side effects.
Lung Cancer, Hepatocellular CarcinomaBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of chronic heart failure. It aims to see if the medicine is safe and if it can improve how the heart works according to blood tests, compared to a dummy pill.
chronic heart failureBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called Efavaleukin Alfa for people with moderate to severe Ulcerative Colitis. We want to see if it's safe and helps people feel better and get their condition under control within 12 weeks.
Ulcerative Colitis (UC)Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
This study is looking at a new treatment for stomach cancer and cancer where the food pipe joins the stomach. It's comparing a drug called pembrolizumab combined with chemotherapy against chemotherapy alone, to see if it helps patients live longer and stops the cancer from coming back.
Gastric and gastroesophageal junction (GEJ) adenocarcinomaBelgium - Active not recruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study looks at a new drug, efgartigimod PH20 SC, for adults with active idiopathic inflammatory myopathy (IIM), a condition causing muscle weakness and inflammation. It compares the drug to a dummy treatment to see if it helps improve muscle strength and overall well-being.
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment.
This study looks at a new medicine called cabozantinib for young people with a type of bone cancer called osteosarcoma. It compares cabozantinib plus supportive care with supportive care alone to see if it helps stop the cancer from growing.
Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults, OsteosarcomaBelgium - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
This study is testing a new drug, TAK-676, for adults with advanced solid cancers. It aims to see if TAK-676 is safe, how well it's tolerated, and how it works, both alone and with another cancer drug called Pembrolizumab (Keytruda).
Solid NeoplasmBelgium - Ongoing, recruitingTherapeutic use (Phase IV)
Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight; ADJUST - Phase 4 – efficacy, A randomised, double-blind, controlled, parallel group, multi-centre trial
This study compares a flexible dose of Brodalumab, a psoriasis treatment, with its usual dose for people with moderate to severe plaque psoriasis who weigh 120 kg or more. It aims to see if the adjustable dose works better at clearing skin.
Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.Belgium - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in Patients with previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer
This study looks at new drug combinations for advanced non-small cell lung cancer. It compares two treatments, one with a new drug called tiragolumab, to see which works best at shrinking tumours, stopping cancer growth, and helping people live longer and have a better quality of life.
Non-squamous non-small cell lung cancer (NSCLC)Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension
This study is testing a new inhaled powder medicine for a lung condition called pulmonary arterial hypertension (PAH). Researchers want to see if it helps patients and if it's safe. It compares different strengths of the new medicine against a dummy powder.
Pulmonary Arterial HypertensionBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
This study is looking at a new way to treat AL amyloidosis, a rare condition where unhealthy proteins build up in your body. It compares a new drug called daratumumab with existing treatments to see if it works better and is safe for people newly diagnosed with the condition.
AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)Belgium - Active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Urothelial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung CancerHepatocellular CarcinomaBelgium - RecruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
Haemophilia ABelgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.
This study is for people with advanced cancers that have a specific genetic change called a KRAS G12C mutation. It's testing new medicines, including one called BI 1823911, to see how different doses work and if they're better when combined with other treatments.
solid tumour harbouring G12C mutationBelgium - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Belgium - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echinocandin followed by Oral Fluconazole (MARIO)
This study looks at new treatments for serious fungal infections called candidemia and invasive candidiasis. We are comparing a new medicine, ibrexafungerp, with an existing one, fluconazole, to see which works better and is safer after initial treatment with another antifungal.
Invasive Candidiasis/ CandidemiaBelgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
In vivo PET of synaptic density in cognitive disorders: prospective evaluation of neuronal dysfunction and relation to symptomatology.
This study uses special brain scans to look at how brain connections (synapses) are affected in people with memory problems and other brain conditions. We want to understand why these conditions happen and how they lead to symptoms, hoping to find better ways to help in the future.
Cognitive Disorders including Alzheimer's Disease, Frontotemporal dementia, Lewy Body Disease and psychiatric disorders.Belgium - Active not recruitingNA
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
This study is looking into a new way to help people with heart failure by stimulating a nerve called the vagal nerve. It involves a small implanted device and aims to improve heart health and quality of life.
Heart FailureCongestive Heart FailureBelgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Single Dose Pharmacokinetics and Relative Bioavailability of Sayana Press via Upper Arm Injection Relative to Anterior Thigh and Abdomen
This study looks at a type of long-term contraception called Sayana Press. It compares how the body uses this medicine when given in the upper arm, thigh, or tummy to find the best way to give it.
long-term female contraceptionBelgium - Recruiting
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
This study looks at how well a drug called VITRAKVI works and how safe it is for people with TRK fusion cancer. This type of cancer happens when certain genes fuse together. Doctors want to see how VITRAKVI helps patients in real-world use.
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionBelgium - RecruitingPHASE1, PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study is for children and young adults aged 1-21 with specific types of aggressive blood cancers that have come back or not responded to treatment. It tests new drug combinations to see if they're safe and work well for those with certain genetic changes in their cancer.
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RefractoryBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
INCMGA 0012-303: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
This study is testing a new medicine, retifanlimab, alongside standard chemotherapy for anal canal cancer that has spread or come back. Researchers want to see if this new combination helps patients live longer without their cancer getting worse, compared to chemotherapy alone.
Squamous Carcinoma of the Anal CanalBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species
This study looks at a new medicine, olorofim, for serious fungal infections caused by Aspergillus. It compares olorofim to an existing treatment, AmBisome, to see which is safer and more effective for patients in the UK.
Invasive fungal infections due to Aspergillus spp.Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in patients with major depressive disorder
This study is looking into a new medication for depression. It aims to see if different doses of this new drug, called BI 1569912, can help people with major depression feel better and if it's safe to use. Patients will take the new drug alongside their usual treatment.
Major depressive disorderBelgium - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerBelgium - RecruitingPHASE3
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
This study looks at a daily tablet called ivosidenib for adults with bile duct cancer that has come back or spread, and has been treated before. It aims to confirm if the treatment is safe and works well, and how it affects quality of life.
CholangiocarcinomaBelgium - RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskBelgium - Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCBelgium - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A proof of concept study with NVD-003, an autologous osteogenic bone graft, in the treatment of congenital pseudarthrosis of the tibia in pediatric patients.
This study is testing a new treatment called NVD-003 for children with a rare bone condition in their lower leg. It aims to see if the treatment is safe and helps the bone heal.
Congenital pseudarthrosis of the tibiaBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study)
This study is for people with a certain type of advanced lung cancer that has stopped responding to a previous treatment called osimertinib. It tests a new combination of two drugs, tepotinib and osimertinib, to see if it can shrink tumours.
Lung CancerBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
This study is testing a new medicine, ianalumab, for adults with active Sjögren’s syndrome. It compares the new medicine to a dummy medicine (placebo) to see if it helps reduce symptoms and improve quality of life.
Sjögren’s SyndromeBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
This study is testing a new medicine, AMX0035, for people with Motor Neurone Disease (ALS). It aims to see if the medicine can slow down the disease's progression over 48 weeks, compared to a dummy medicine.
Amyotrophic Lateral Sclerosis (ALS)Belgium - RecruitingPHASE3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
This study looks at an inhaled medicine called treprostinil for people with progressive pulmonary fibrosis. It aims to see if it's safe and effective in slowing down this lung condition over 52 weeks. Half get the medicine, half get a dummy treatment.
Progressive Pulmonary FibrosisInterstitial Lung DiseaseBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 over 21 days in Ambulatory Adult Patients with Charcot-Marie-Tooth Disease Type 1 and Type 2
This study is testing a new medicine, NMD670, for people with Charcot-Marie-Tooth disease types 1 and 2. It compares the medicine to a dummy pill to see if it helps people walk further and if it's safe over 21 days. Participants will be adults who can walk.
Charcot-Marie-Tooth Disease Type 1 and Type 2Belgium